14 Worst 52-Week High Stocks to Buy According to Short Sellers
The start of the US Federal Reserve cutting cycle ushers a new era in the investment world after one of the longest bull runs.
Rhythm Pharmaceuticals Inc. (RYTM)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 6,398,365 | $262,716,867 | 3.35% | |
| 2. | RA Capital Management Peter Kolchinsky | 6,084,412 | $249,825,957 | +15% | 3.3% |
| 3. | Perceptive Advisors Joseph Edelman | 3,446,579 | $141,516,534 | +6% | 3.4% |
| 4. | Polar Capital Brian Ashford-Russell And Tim Woolley | 1,500,000 | $61,590,000 | 0.36% | |
| 5. | Rock Springs Capital Management Kris Jenner, Gordon Bussard, Graham Mcphail | 1,280,493 | $52,577,043 | -16% | 1.58% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.17 | 10,000 | Officer, Director | 111,335 | 2021-03-30 | Filing | |
| $26.42 | 378,501 | Director | 3,074,893 | 2018-06-25 | Filing | |
| $17.00 | 100,000 | Large Shareholder | 2,696,392 | 2017-10-10 | Filing | |
| $17.00 | 100,000 | Large Shareholder, Director | 2,696,392 | 2017-10-10 | Filing | |
| $17.00 | 550,000 | Large Shareholder | 4,909,956 | 2017-10-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $52.40 | 31,751 | Director | 3,000 | 2024-09-17 | Filing | |
| $50.03 | 4,099 | Officer | 13,500 | 2024-09-09 | Filing | |
| $50.60 | 350 | Director | 3,000 | 2024-09-10 | Filing | |
| $50.20 | 8,661 | Director | 3,350 | 2024-09-10 | Filing | |
| $49.05 | 8,490 | Director | 12,011 | 2024-09-10 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,052,648 | $370,180,229 | 0.29% | |
| 2. | 6,351,750 | $291,989,948 | 0% | |
| 3. | 5,047,934 | $232,053,526 | 0.04% | |
| 4. | 3,226,938 | $148,342,339 | 0% | |
| 5. | 2,909,956 | $133,770,677 | 8.91% |
News See All
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q2 2024 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Rhythm Pharmaceuticals Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2024 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-2.35058 EPS, expectations were $-2.12. Rhythm Pharmaceuticals, Inc.
Jim Cramer Portfolio: 11 Latest Stocks to Buy
In this article, we will take a detailed look at Jim Cramer Portfolio: 11 Latest Stocks to Buy.
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q4 2023 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. reports earnings inline with expectations. Reported EPS is $-0.7 EPS, expectations were $-0.7. Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q2 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Rhythm Pharmaceuticals Q2 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Rhythm Pharmaceuticals Q1 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Top 5 Growth Stocks in Biotech
Headquartered in Bermuda, Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) is a biopharmaceutical company focusing on therapeutics for debilitating disorders.
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q3 2023 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by. Good morning, and welcome to the Red Cat Holdings Fiscal 2023 Third Quarter Financial Results and Corporate Update Conference Call.
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q4 2022 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Rhythm Pharmaceuticals Fourth Quarter and Full Year 2022 Earnings Conference Call.
Billionaire Hedge Funds
